Fig. 3From: Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinomaTumor load and radiotherapy time during follow-up of immunotherapy and stereotactic ablative radiotherapy patientsBack to article page